Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

Clinical trial NCT05185739 · RECRUITING

Trial details

NCT number: NCT05185739
Sponsor: University College, London
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2022-08-25
Primary completion: 2028-07-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.